End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Drugs In Development, 2024 report and make more profitable business decisions.
End-stage kidney disease, also called end-stage renal disease (ESRD), refers to complete or almost complete kidney failure. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion, and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis, and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.
The End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) drugs in development market research report provide comprehensive information on the therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 11 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aronora IncCSL Ltd
Daiichi Sankyo Co Ltd
Eagle Pharmaceuticals Inc
Galderma SA
Inozyme Pharma Inc
Ionis Pharmaceuticals Inc
KidneyCure Ltd
MedAbome Inc
Resverlogix Corp
VESSL Therapeutics Ltd
Table of Contents
Table
Figures
Frequently asked questions